Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.
Young KG, McInnes EH, Massey RJ, Kahkoska AR, Pilla SJ, Raghavan S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD PDMI. Young KG, et al. Among authors: mcgovern ap. Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. Commun Med (Lond). 2023. PMID: 37794166 Free PMC article.
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.
Young KG, McInnes EH, Massey RJ, Kahkohska AR, Pilla SJ, Raghaven S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD Precision Medicine in Diabetes Initiative Consortium. Young KG, et al. Among authors: mcgovern ap. medRxiv [Preprint]. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868. medRxiv. 2023. Update in: Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w PMID: 37131814 Free PMC article. Updated. Preprint.
Corrigendum to 'Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches' [Journal of Clinical Epidemiology (2023) 34-44].
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG. Thomas NJ, et al. J Clin Epidemiol. 2023 Jul;159:356. doi: 10.1016/j.jclinepi.2023.04.009. Epub 2023 Jun 12. J Clin Epidemiol. 2023. PMID: 37316353 Free article. No abstract available.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, Holman RR, Bowden J, Hattersley AT, Pearson ER, Jones AG, Shields BM, McKinley TJ, Dennis JM; MASTERMIND consortium. Cardoso P, et al. Among authors: mcgovern ap. Diabetologia. 2024 May;67(5):822-836. doi: 10.1007/s00125-024-06099-3. Epub 2024 Feb 22. Diabetologia. 2024. PMID: 38388753 Free PMC article.
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.
Güdemann LM, Young KG, Thomas NJM, Hopkins R, Challen R, Jones AG, Hattersley AT, Pearson ER, Shields BM, Bowden J, Dennis JM, McGovern AP; MASTERMIND consortium. Güdemann LM, et al. Among authors: mcgovern ap. Diabetologia. 2024 Sep;67(9):1817-1827. doi: 10.1007/s00125-024-06190-9. Epub 2024 Jun 5. Diabetologia. 2024. PMID: 38836934 Free PMC article.
37 results